This study investigates stomach cancer, gastroesophageal junction cancer, and pancreatic cancer. It examines how an investigational medication, ASP2138, interacts with these conditions.
This study evaluates the safety and tolerability of ASP2138, both alone and in combination with standard cancer treatments. Researchers seek to find a suitable dose and assess any potential medical issues from the treatments.
- Who can participate: Adults 18 years or older with locally advanced, unresectable, or metastatic stomach, gastroesophageal junction, or pancreatic cancer can participate, provided their tumor has the CLDN18.2 marker.
- Study details: Participants will receive ASP2138 either alone or with standard cancer treatments. The study includes different phases to determine the best dose. A placebo is not involved in this study.
How understandable was the trial content above?
Hard to understand
Easy to understand